Shukra Pharmaceuticals Limited (BOM:524632)
27.80
-0.56 (-1.97%)
At close: Sep 5, 2025
Shukra Pharmaceuticals Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Cash & Equivalents | - | 121.18 | 99.8 | 39.73 | 2.9 | 5.04 | Upgrade |
Cash & Short-Term Investments | 121.18 | 121.18 | 99.8 | 39.73 | 2.9 | 5.04 | Upgrade |
Cash Growth | 21.41% | 21.41% | 151.21% | 1271.89% | -42.59% | 299.07% | Upgrade |
Accounts Receivable | - | 87.67 | 245.13 | 301.87 | 74.01 | 97.48 | Upgrade |
Other Receivables | - | - | 64.67 | 82.3 | - | - | Upgrade |
Receivables | - | 189.97 | 329.59 | 406.95 | 99.5 | 132.1 | Upgrade |
Inventory | - | 99.53 | 23.14 | 31.57 | 39.54 | 16.82 | Upgrade |
Prepaid Expenses | - | - | 0.17 | 0.22 | 0.59 | 0.31 | Upgrade |
Other Current Assets | - | 243.6 | 109.62 | 52.25 | 16.2 | 6.33 | Upgrade |
Total Current Assets | - | 654.27 | 562.33 | 530.72 | 158.72 | 160.6 | Upgrade |
Property, Plant & Equipment | - | 213.43 | 216.04 | 218.95 | 192.41 | 193.53 | Upgrade |
Long-Term Investments | - | - | - | - | - | 1.95 | Upgrade |
Other Long-Term Assets | - | - | 0 | - | - | - | Upgrade |
Total Assets | - | 867.7 | 778.37 | 749.66 | 351.13 | 356.08 | Upgrade |
Accounts Payable | - | 92.16 | 72.21 | 336.22 | 85.9 | 53.29 | Upgrade |
Accrued Expenses | - | - | 10.81 | 9.18 | 10.33 | 7.83 | Upgrade |
Current Portion of Long-Term Debt | - | 10.64 | 4.97 | 13.13 | 2.5 | - | Upgrade |
Current Unearned Revenue | - | - | 35.28 | 66.12 | 24.68 | 8.45 | Upgrade |
Other Current Liabilities | - | 70.04 | 18.25 | 0.42 | 0.36 | 0.78 | Upgrade |
Total Current Liabilities | - | 172.84 | 141.53 | 425.06 | 123.77 | 70.35 | Upgrade |
Long-Term Debt | - | 31.13 | 26.57 | 37.68 | 31.27 | 97.71 | Upgrade |
Long-Term Deferred Tax Liabilities | - | 34.11 | 32.73 | 32.87 | 32.6 | 32.03 | Upgrade |
Other Long-Term Liabilities | - | - | 0 | -0 | -0 | - | Upgrade |
Total Liabilities | - | 239.34 | 201.98 | 496.7 | 187.63 | 200.09 | Upgrade |
Common Stock | - | 437.88 | 109.47 | 39.14 | 15.66 | 15.66 | Upgrade |
Additional Paid-In Capital | - | - | 91.19 | 22.79 | - | - | Upgrade |
Retained Earnings | - | - | 375.61 | 191.13 | 147.84 | 140.34 | Upgrade |
Comprehensive Income & Other | - | 190.48 | 0.13 | -0.09 | - | - | Upgrade |
Shareholders' Equity | 628.36 | 628.36 | 576.4 | 252.97 | 163.5 | 155.99 | Upgrade |
Total Liabilities & Equity | - | 867.7 | 778.37 | 749.66 | 351.13 | 356.08 | Upgrade |
Total Debt | 41.77 | 41.77 | 31.54 | 50.82 | 33.77 | 97.71 | Upgrade |
Net Cash (Debt) | 79.41 | 79.41 | 68.27 | -11.09 | -30.87 | -92.66 | Upgrade |
Net Cash Growth | 16.33% | 16.33% | - | - | - | - | Upgrade |
Net Cash Per Share | 0.14 | 0.18 | 0.16 | -0.16 | -0.49 | -1.48 | Upgrade |
Filing Date Shares Outstanding | 514.8 | 448.87 | 438.39 | 438.39 | 62.63 | 62.63 | Upgrade |
Total Common Shares Outstanding | 514.8 | 448.87 | 438.39 | 438.39 | 62.63 | 62.63 | Upgrade |
Working Capital | - | 481.44 | 420.79 | 105.66 | 34.95 | 90.25 | Upgrade |
Book Value Per Share | 1.40 | 1.40 | 1.31 | 0.58 | 2.61 | 2.49 | Upgrade |
Tangible Book Value | 628.36 | 628.36 | 576.4 | 252.97 | 163.5 | 155.99 | Upgrade |
Tangible Book Value Per Share | 1.40 | 1.40 | 1.31 | 0.58 | 2.61 | 2.49 | Upgrade |
Land | - | - | 1.72 | 1.72 | 1.7 | 1.72 | Upgrade |
Buildings | - | - | 125.26 | 116.73 | 100.5 | 100.4 | Upgrade |
Machinery | - | - | 286.29 | 277.22 | 248.6 | 233.14 | Upgrade |
Construction In Progress | - | - | 16.62 | 16.62 | 16.62 | 16.62 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.